Mannitol Preserves the Viscoelastic Properties of Hyaluronic Acid in an In Vitro Model of Oxidative Stress

Rheumatology and Therapy

Volumn 1, Issue 1, 2014, Pages 45-54

  Conrozier, Thierry ^a   Mathieu, Pierre ^b   Rinaudo, Marguerite ^c  

^a Centre Hospitalier de Belfort Montbeliard   (France)

^b Rhumatologue   (France)

^c Biomaterials Applications   (France)

Author keywords

Antioxidant; Hyaluronic acid; Hydrogen peroxide; Mannitol; Osteoarthritis; Reactive oxygen species; Rheology; Viscoelastic properties; Viscosupplementation

Indexed keywords

EID: 84941731833     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-014-0001-8     Document Type: Article

References (46)

1. Pelletier JP, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol. 1993;20(suppl 39):19–23.
2. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;9:3–9.
3. Balazs EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int. 2004;12:278–89.
4. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology. 2007;44:59–74.
5. Mathieu P, Conrozier T, Vignon E, Rozand Y, Rinaudo M. Rheologic behavior of osteoarthritic synovial fluid after addition of hyaluronic acid: a pilot study. Clin Orthop Relat Res. 2009;467:3002–9. DOI: 10.1007/s11999-009-0867-x
6. Rinaudo M, Rozand Y, Mathieu P, Conrozier T. Role of different pre-treatments on composition and rheology of synovial fluids. Polymers. 2009;1:16–34. DOI: 10.3390/polym1010016
7. Conrozier T, Mathieu P, Vignon E, Piperno M, Rinaudo M. Differences in the osteoarthritic synovial fluid composition and rheology between patients with or without flare: a pilot study. Clin Exp Rheumatol. 2012;30:729–34.
8. Milas M, Rinaudo M. Characterization and properties of hyaluronic acid (hyaluronan). In: Dimitriu S, editor. Polysaccharides: structural diversity and functional versatility. New York, NY: Marcel Dekker; 2004. p. 535–49.
9. Bagga H, Burkhardt D, Sambrook P, March L. Long term effects of intra-articular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33:946–50.
10. Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthr Cartil. 1993;1:97–103. DOI: 10.1016/S1063-4584(05)80024-X
11. Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthr Cartil. 2006;14:1237–47. DOI: 10.1016/j.joca.2006.05.009
12. Li P, Raitcheva D, Hawes M, et al. Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms. Osteoarthr Cartil. 2012;20:1336–46. DOI: 10.1016/j.joca.2012.07.004
13. Li J, Gorski DJ, Anemaet W, et al. Hyaluronan injection in murine osteoarthritis prevents TGFbeta 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. Arthritis Res Ther. 2012;14:R151. DOI: 10.1186/ar3887
14. Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. 2007;465:241–8.
15. Yasuda T. Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages. Tohoku J Exp Med. 2010;220:229–35. DOI: 10.1620/tjem.220.229
16. Boettger MK, Kümmel D, Harrison A, Schaible HG. Evaluation of long-term antinociceptive properties of stabilized hyaluronic acid preparation (NASHA) in an animal model of repetitive joint pain. Arthritis Res Ther. 2011;13:R110. DOI: 10.1186/ar3394
17. Lindenhayn K, Heilmann HH, Niederhausen T, Walther HU, Pohlenz K. Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. Eur J Clin Chem Clin Biochem. 1997;35:355–63.
18. Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;4:603–13. DOI: 10.2165/00003088-200241080-00004
19. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res Part B. 2012;100B:457–62. DOI: 10.1002/jbm.b.31971
20. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;2:CD005321.
21. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64:465–74. DOI: 10.1002/acr.21596
22. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–81. DOI: 10.1136/ard.2004.028886
23. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55. DOI: 10.1136/ard.2003.011742
24. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–62. DOI: 10.1016/j.joca.2007.12.013
25. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476–99. DOI: 10.1016/j.joca.2010.01.013
26. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2000;59:936–44. DOI: 10.1136/ard.59.12.936
27. Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:57–63.
28. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43:593–9. DOI: 10.1016/j.semarthrit.2013.10.002
29. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180–91. DOI: 10.7326/0003-4819-157-3-201208070-00473
30. Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. Bio Drugs. 2012;26:257–68.
31. Stern R, Kogan G, Jedrzejas MJ, Soltés L. The many ways to cleave hyaluronan. Biotechnol Adv. 2007;25:537–57. DOI: 10.1016/j.biotechadv.2007.07.001
32. Mendoza G, Alvarez AI, Pulido MM, et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr Res. 2007;342:96–102. DOI: 10.1016/j.carres.2006.10.027
33. Grange L, Nguyen MV, Lardy B, et al. NAD(P)H oxidase activity of Nox4 in chondrocytes is both inducible and involved in collagenase expression. Antioxid Redox Signal. 2006;8:1485–96. DOI: 10.1089/ars.2006.8.1485
34. Rousset F, Nguyen MV, Grange L, Morel F, Lardy B. Heme oxygenase-1 regulates matrix metalloproteinase MMP-1 secretion and chondrocyte cell death via Nox4 NADPH oxidase activity in chondrocytes. PLoS One. 2013;20(8):e66478. DOI: 10.1371/journal.pone.0066478
35. Chevalier X. Intraarticular treatments for osteoarthritis: new perspectives. Curr Drug Targets. 2010;11:546–60. DOI: 10.2174/138945010791011866
36. Conrozier T, Lardy B, Rinaudo M. Effect of high concentrations of mannitol on the stability of hyaluronan in an oxidative stress model induced by xanthine/xanthine oxidase. Osteoarthr Cartil. 2014;22:S478. DOI: 10.1016/j.joca.2014.02.908
37. Soltés L, Kogan G, Stankovska M, et al. Degradation of high-molar-mass hyaluronan and characterization of fragments. Biomacromolecules. 2007;8:2697–705. DOI: 10.1021/bm070309b
38. Belda JI, Artola A, García-Manzanares MD, et al. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. J Cataract Refract Surg. 2005;31:1213–8. DOI: 10.1016/j.jcrs.2004.11.055
39. Magovern GJ Jr, Bolling SF, Casale AS, Bulkley BH, Gardner TJ. The mechanism of mannitol in reducing ischemic injury: hyperosmolarity or hydroxyl scavenger? Circulation. 1984;70(suppl1):91–5.
40. Suzuki J, Imaizumi S, Kayama T, Yoshimoto T. Chemiluminescence in hypoxic brain—the second report: cerebral protective effect of mannitol, vitamin E and glucocorticoid. Stroke. 1985;16:695–700. DOI: 10.1161/01.STR.16.4.695
41. Fu W, Jiao X. The effect of mannitol and anisodim on the prevention of free radical injury to post-ischemia flaps: an experimental study. Br J Plast Surg. 1995;48:218–21. DOI: 10.1016/0007-1226(95)90005-5
42. Mannitol: INCHEM International program for Chemical safety (IPCS): http://www.inchem.org/documents/jecfa/jecmono/v21je10.htm (2014). Accessed June 6 2014.
43. VIDAL: http://www.vidal.fr/recherche/index/q:mannitol/sorbitol/classe_therapeutique (2014). Accessed June 6 2014.
44. Sies H. Relationship between free radicals and vitamins: an overview. Int J Vitam Nutr Res Suppl. 1989;30:215–23.
45. Borras-Verdera A, Calcedo-Bernal V, Ojeda-Levenfeld J, Clavel-Sainz C. Efficacy and safety of a single intra-articular injection of 2% hyaluronic acid plus mannitol in knee osteoarthritis over a 6-month period. Rev Esp Cir Ortop Traumatol. 2012;56:274–80.
46. Heisel J, Kipshoven C. Safety and efficacy findings from a non-interventional study of a new hyaluronic acid/sorbitol formulation (GO-ON matrix) for intra-articular injection to relieve pain and disability in osteoarthritis patients. Drug Res. 2013;63:445–9. DOI: 10.1055/s-0033-1343425